RGUP21115 / NRG-GU011 / PROMETHEAN / Zhang
Basic Study Information
Purpose:
This phase II trial tests whether relugolix and radiation therapy works to shrink
tumors in patients with prostate cancer that has spread in a limited way to 1 to 5
other parts of the body (oligometastatic). Testosterone can cause the growth of prostate
cancer cells. Relugolix lowers the amount of testosterone made by the body. This may
help stop the growth of tumor cells that need testosterone to grow. Giving relugolix
with radiation therapy may help lower the chance of prostate cancer growing or spreading.
Location: Highland Hospital
Lead Researcher (Principal Investigator)
Lead Researcher:
Hong Zhang
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search